Baudax Bio (BXRXQ) Stock Price

Baudax Bio Price

NYSE·CLOSED
0.00
​
Market closed

Revenue has compounded at 60.4% per year over the past 2 years to 1.27 M USD. Baudax Bio's net margin stands at -4,633.2%, up from -15,436.1% several years earlier.

Baudax Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baudax Bio business model & stock analysis

Baudax Bio, Inc. develops and commercializes pharmaceutical products for hospital and acute care settings, with its lead candidate ANJESO injection, a COX-2 selective non-steroidal anti-inflammatory drug for moderate to severe pain management. The company's pipeline includes neuromuscular blocking agents (NMBAs) such as BX-1000, an intermediate-acting NMBA, and BX-2000, an ultrashort-acting NMBA, alongside a specific reversal agent for these agents. Baudax Bio also focuses on Treg-based cell therapies for autoimmune diseases, targeting hospital-based treatment segments where pain management and surgical support are critical. The company's primary revenue streams are expected to come from the development and eventual commercialization of its pharmaceutical product candidates, including ANJESO injection, BX-1000, BX-2000, and the reversal agent, as well as Treg-based therapies. Hospital and acute care settings are the key segments purchasing these products, with a focus on pain management and surgical procedures requiring muscle relaxation and intubation support. The firm's target market includes healthcare providers and institutions managing acute care needs. Baudax Bio's product portfolio is centered around specialized pharmaceuticals for hospital use, with ANJESO injection targeting pain management and the NMBA pipeline addressing surgical procedures. The company's strategy involves advancing these candidates through development stages toward potential commercialization, aiming to generate revenue from sales in the hospital and acute care markets once approved and launched.

Frequently asked questions about Baudax Bio

8 analysts currently rate the Baudax Bio stock: 0 recommend buying, 3 holding and 5 selling.

Converted at the current exchange rate, the Baudax Bio share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Baudax Bio.

The profit cannot currently be calculated for Baudax Bio.

The P/E ratio cannot be calculated for Baudax Bio at the moment.

The P/S cannot be calculated for Baudax Bio currently.

The Eulerpool Quality Score for Baudax Bio is 4/10.

The ISIN of Baudax Bio is US07160F4046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Baudax Bio is BXRXQ. The ticker symbol is used to trade Baudax Bio shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
141,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 14, 2019
ISIN
US07160F4046
Cusip
07160F404
Market capitalization
4,359.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2023
—
P/Ee 2023
-0.00
P/Ee 2024
—
P/Ee 2024
-0.00
P/Ee 2025
-0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
258.75 %
Last updated Nov 20, 2026, 6:20 PM

Baudax Bio Peer Group

All fundamentals and in-depth analysis of Baudax Bio

Our stock analysis for Baudax Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Baudax Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.